Drug Delivery Solutions
NanoOncology
NanoOncology

August 6 2012

  •  
  • NanoOncology™ acquired by PeptiMed™, Inc., a Madison-based biotechnology corporation with a major emphasis on developing drug delivery technology.

August 29 2012

  •  
  • NanoOncology™ is chosen to exhibit at the Bioforward Biovision Summit on September 12th at Monona Terrace, Madison, Wisconsin. NanoOncology™ is one of six biotechnology corporations in the Emerging Company Showcase. See www.bioforward.org for more information and registration.

PRESS RELEASES

  • September 19 2012

    PeptiMed™, the parent company of NanoOncology, was certified as a Qualified New Business Venture by the Wisconsin Economic Development Corporation. Investors in PeptiMed will receive credits on their Wisconsin income tax for 25 % of the amount of the investment up to $2 million. These credits are exchangeable for investors outside the State of Wisconsin. PeptiMed™ is seeking investment to bring its lead anticancer drug into the clinic.